These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 32105980)

  • 21. Towards new 5-HT7 antagonists among arylsulfonamide derivatives of (aryloxy)ethyl-alkyl amines: Multiobjective based design, synthesis, and antidepressant and anxiolytic properties.
    Canale V; Kurczab R; Partyka A; Satała G; Lenda T; Jastrzębska-Więsek M; Wesołowska A; Bojarski AJ; Zajdel P
    Eur J Med Chem; 2016 Jan; 108():334-346. PubMed ID: 26698537
    [TBL] [Abstract][Full Text] [Related]  

  • 22. S18327 (1-[2-[4-(6-fluoro-1, 2-benzisoxazol-3-yl)piperid-1-yl]ethyl]3-phenyl imidazolin-2-one), a novel, potential antipsychotic displaying marked antagonist properties at alpha(1)- and alpha(2)-adrenergic receptors: II. Functional profile and a multiparametric comparison with haloperidol, clozapine, and 11 other antipsychotic agents.
    Millan MJ; Brocco M; Rivet JM; Audinot V; Newman-Tancredi A; Maiofiss L; Queriaux S; Despaux N; Peglion JL; Dekeyne A
    J Pharmacol Exp Ther; 2000 Jan; 292(1):54-66. PubMed ID: 10604931
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Synthesis and pharmacological evaluation of piperidine (piperazine)-substituted benzoxazole derivatives as multi-target antipsychotics.
    Huang L; Zhang W; Zhang X; Yin L; Chen B; Song J
    Bioorg Med Chem Lett; 2015 Nov; 25(22):5299-305. PubMed ID: 26483200
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Synthesis and pharmacological characterization of novel N-(trans-4-(2-(4-(benzo[d]isothiazol-3-yl)piperazin-1-yl)ethyl)cyclohexyl)amides as potential multireceptor atypical antipsychotics.
    Chen XW; Sun YY; Fu L; Li JQ
    Eur J Med Chem; 2016 Nov; 123():332-353. PubMed ID: 27487565
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Novel multi-target azinesulfonamides of cyclic amine derivatives as potential antipsychotics with pro-social and pro-cognitive effects.
    Zajdel P; Kos T; Marciniec K; Satała G; Canale V; Kamiński K; Hołuj M; Lenda T; Koralewski R; Bednarski M; Nowiński L; Wójcikowski J; Daniel WA; Nikiforuk A; Nalepa I; Chmielarz P; Kuśmierczyk J; Bojarski AJ; Popik P
    Eur J Med Chem; 2018 Feb; 145():790-804. PubMed ID: 29407591
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The impact of the halogen bonding on D
    Partyka A; Kurczab R; Canale V; Satała G; Marciniec K; Pasierb A; Jastrzębska-Więsek M; Pawłowski M; Wesołowska A; Bojarski AJ; Zajdel P
    Bioorg Med Chem; 2017 Jul; 25(14):3638-3648. PubMed ID: 28529043
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Brexpiprazole II: antipsychotic-like and procognitive effects of a novel serotonin-dopamine activity modulator.
    Maeda K; Lerdrup L; Sugino H; Akazawa H; Amada N; McQuade RD; Stensbøl TB; Bundgaard C; Arnt J; Kikuchi T
    J Pharmacol Exp Ther; 2014 Sep; 350(3):605-14. PubMed ID: 24947464
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Repeated administration of Yokukansan inhibits DOI-induced head-twitch response and decreases expression of 5-hydroxytryptamine (5-HT)2A receptors in the prefrontal cortex.
    Egashira N; Iwasaki K; Ishibashi A; Hayakawa K; Okuno R; Abe M; Uchida N; Mishima K; Takasaki K; Nishimura R; Oishi R; Fujiwara M
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Aug; 32(6):1516-20. PubMed ID: 18558456
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Synthesis and biological evaluation of a series of multi-target N-substituted cyclic imide derivatives with potential antipsychotic effect.
    Xu M; Wang Y; Yang F; Wu C; Wang Z; Ye B; Jiang X; Zhao Q; Li J; Liu Y; Zhang J; Tian G; He Y; Shen J; Jiang H
    Eur J Med Chem; 2018 Feb; 145():74-85. PubMed ID: 29324345
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Quetiapine versus risperidone in elderly patients with behavioural and psychological symptoms of dementia: efficacy, safety and cognitive function.
    Rainer M; Haushofer M; Pfolz H; Struhal C; Wick W
    Eur Psychiatry; 2007 Sep; 22(6):395-403. PubMed ID: 17482432
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pyrrolo[1,3]benzothiazepine-based serotonin and dopamine receptor antagonists. Molecular modeling, further structure-activity relationship studies, and identification of novel atypical antipsychotic agents.
    Campiani G; Butini S; Fattorusso C; Catalanotti B; Gemma S; Nacci V; Morelli E; Cagnotto A; Mereghetti I; Mennini T; Carli M; Minetti P; Di Cesare MA; Mastroianni D; Scafetta N; Galletti B; Stasi MA; Castorina M; Pacifici L; Vertechy M; Di Serio S; Ghirardi O; Tinti O; Carminati P
    J Med Chem; 2004 Jan; 47(1):143-57. PubMed ID: 14695828
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Use of Antipsychotics in Patients with Behavioral and Psychological Symptoms of Dementia: Results of a Spanish Delphi Consensus.
    Manzano-Palomo S; Agüera-Ortiz LF; García-Caballero A; Martínez-Raga J; Ojea-Ortega T; Sánchez-Valle R; Antón-Jiménez M; Monge-Argilés JA; Ramos-García I
    Dement Geriatr Cogn Disord; 2020; 49(6):573-582. PubMed ID: 33176326
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Novel spirohydantoin derivative as a potent multireceptor-active antipsychotic and antidepressant agent.
    Czopek A; Kołaczkowski M; Bucki A; Byrtus H; Pawłowski M; Kazek G; Bojarski AJ; Piaskowska A; Kalinowska-Tłuścik J; Partyka A; Wesołowska A
    Bioorg Med Chem; 2015 Jul; 23(13):3436-47. PubMed ID: 25936259
    [TBL] [Abstract][Full Text] [Related]  

  • 34. PD 158771, a potential antipsychotic agent with D2/D3 partial agonist and 5-HT(1A) agonist actions. II. Preclinical behavioral effects.
    Corbin AE; Meltzer LT; Ninteman FW; Wiley JN; Christoffersen CL; Wustrow DJ; Wise LD; Pugsley TA; Heffner TG
    Neuropharmacology; 2000 Apr; 39(7):1211-21. PubMed ID: 10760363
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Using antipsychotic agents in older patients.
    Alexopoulos GS; Streim J; Carpenter D; Docherty JP;
    J Clin Psychiatry; 2004; 65 Suppl 2():5-99; discussion 100-102; quiz 103-4. PubMed ID: 14994733
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Synthesis and evaluation of a series of piperidine-2,6-dione-piperazine (piperidine) derivatives as multireceptor atypical antipsychotics.
    Chen Y; Xu X; Liu X; Liu BF; Zhang G
    Arch Pharm (Weinheim); 2012 Nov; 345(11):859-69. PubMed ID: 22886598
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A risk-benefit assessment of risperidone for the treatment of behavioural and psychological symptoms in dementia.
    Zaudig M
    Drug Saf; 2000 Sep; 23(3):183-95. PubMed ID: 11005702
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Management of Behavioral and Psychological Symptoms of Dementia.
    Bessey LJ; Walaszek A
    Curr Psychiatry Rep; 2019 Jul; 21(8):66. PubMed ID: 31264056
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Behavioral and psychological symptoms in dementia: the role of atypical antipsychotics.
    Lawlor BA
    J Clin Psychiatry; 2004; 65 Suppl 11():5-10. PubMed ID: 15264965
    [TBL] [Abstract][Full Text] [Related]  

  • 40. ACP-103, a 5-hydroxytryptamine 2A receptor inverse agonist, improves the antipsychotic efficacy and side-effect profile of haloperidol and risperidone in experimental models.
    Gardell LR; Vanover KE; Pounds L; Johnson RW; Barido R; Anderson GT; Veinbergs I; Dyssegaard A; Brunmark P; Tabatabaei A; Davis RE; Brann MR; Hacksell U; Bonhaus DW
    J Pharmacol Exp Ther; 2007 Aug; 322(2):862-70. PubMed ID: 17519387
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.